Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.41 |
| ▸ | WNT3A | P56704 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133505 | 0.85 | NPC1 (0.50) | NPC1RAB9AKMT2AL3MBTL1NNMT | |
| SCHEMBL6134086 | 0.84 | ALDH1A1 (0.41) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL6134928 | 0.84 | NNMT (0.42) | NPC1RAB9AMEN1KMT2ANNMT | |
| SCHEMBL6134151 | 0.80 | NNMT (0.45) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL5799347 | 0.76 | NPC1 (0.48) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL6134262 | 0.75 | NNMT (0.42) | NPC1RAB9AMEN1KMT2ANNMT | |
| SCHEMBL6134635 | 0.75 | SMN1; SMN2 (0.44) | MEN1KMT2AFEN1NNMTALDH1A1 | |
| SCHEMBL6134193 | 0.74 | CTNNB1 (0.50) | NPC1RAB9AMEN1KMT2ANNMT | |
| SCHEMBL6134121 | 0.73 | NNMT (0.44) | NPC1RAB9AKMT2AL3MBTL1NNMT | |
| SCHEMBL6133543 | 0.73 | NPC1 (0.54) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | NPC1 4182/4885RAB9A 1824/4885MEN1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.